
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Speros lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Speros partnership directed programs consist of SPR206 and tebipenem HBr, which through the companys business development efforts, have joint venture relationships supporting their ongoing development. SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting. Tebipenem...
Antibacterial therapies,novel therapeutics,and infectious disease
Spero therapeutics operates in the Biotechnology research industry.
Spero therapeutics's revenue is 11m - 100m
Spero therapeutics has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.